DE69527650T2 - Katonische amphiphile und plasmide für die intrazelluläre abgabe von therapeutischen mitteln - Google Patents

Katonische amphiphile und plasmide für die intrazelluläre abgabe von therapeutischen mitteln

Info

Publication number
DE69527650T2
DE69527650T2 DE69527650T DE69527650T DE69527650T2 DE 69527650 T2 DE69527650 T2 DE 69527650T2 DE 69527650 T DE69527650 T DE 69527650T DE 69527650 T DE69527650 T DE 69527650T DE 69527650 T2 DE69527650 T2 DE 69527650T2
Authority
DE
Germany
Prior art keywords
therapeutic
gene therapy
amphiphiles
therapeutic compositions
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69527650T
Other languages
English (en)
Other versions
DE69527650D1 (de
Inventor
Craig S Siegel
David J Harris
Edward R Lee
Shirley C Hubbard
Seng H Cheng
Simon J Eastman
John Marshall
Ronald K Scheule
Nelson S Yew
Mathieu B Lane
Eric A Rowe
Rebecca G Bagley
Chau-Dung Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27533061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69527650(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/352,479 external-priority patent/US5650096A/en
Priority claimed from US08/540,867 external-priority patent/US5747471A/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DE69527650D1 publication Critical patent/DE69527650D1/de
Publication of DE69527650T2 publication Critical patent/DE69527650T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
DE69527650T 1994-12-09 1995-12-08 Katonische amphiphile und plasmide für die intrazelluläre abgabe von therapeutischen mitteln Revoked DE69527650T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/352,479 US5650096A (en) 1994-12-09 1994-12-09 Cationic amphiphiles for intracellular delivery of therapeutic molecules
US434495P 1995-09-26 1995-09-26
US439995P 1995-09-27 1995-09-27
US08/540,867 US5747471A (en) 1994-12-09 1995-10-11 Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US08/545,473 US6071890A (en) 1994-12-09 1995-10-19 Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
PCT/US1995/016174 WO1996018372A2 (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules

Publications (2)

Publication Number Publication Date
DE69527650D1 DE69527650D1 (de) 2002-09-05
DE69527650T2 true DE69527650T2 (de) 2003-02-27

Family

ID=27533061

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527650T Revoked DE69527650T2 (de) 1994-12-09 1995-12-08 Katonische amphiphile und plasmide für die intrazelluläre abgabe von therapeutischen mitteln

Country Status (8)

Country Link
US (1) US6071890A (de)
EP (1) EP0799059B1 (de)
JP (1) JPH10510813A (de)
AT (1) ATE221390T1 (de)
DE (1) DE69527650T2 (de)
DK (1) DK0799059T3 (de)
PT (1) PT799059E (de)
WO (1) WO1996018372A2 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
EP0779361A3 (de) 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Verkürzte Form von Kappa B Inhibitor-Protein, rekombinanter Herstellung und Verwendung
FR2744453B1 (fr) * 1996-02-05 1998-07-10 Transgene Sa Composes lipopolyamines, compositions pharmaceutiques en comprenant, vecteurs de transfert d'acide nucleique et procede de preparation
DE19607686A1 (de) * 1996-02-29 1997-09-04 Chemicon Lab Gmbh Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung
ES2154453T3 (es) * 1996-03-01 2001-04-01 Centre Nat Rech Scient Compuestos pertenecientes a la familia de los amidiniums, composiciones farmaceuticas que les contienen y sus aplicaciones.
FR2751972B1 (fr) * 1996-07-30 1998-09-04 Centre Nat Rech Scient Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications
DK0904282T3 (da) * 1996-04-12 2002-03-04 Univ Pittsburgh Hidtil ukendte kationiske cholesterylderivater indeholdende cykliske polære grupper
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
JP4340330B2 (ja) * 1996-05-24 2009-10-07 アイシー‐ヴェック・リミテッド トランスフェクション剤としてのポリカチオン性ステロール誘導体
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
EP0941122B1 (de) 1996-08-13 2003-10-29 Chiron Corporation Zusammensetzungen zur polynukleotidabgabe
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
TR199902068T2 (xx) * 1997-02-28 1999-12-21 Boehringer Ingelheim Pharmaceuticals, Inc. �ltihap h�crelerinin gen tedavisi ile kendi kendini d�zenleyen apoptozu.
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
AU7490098A (en) * 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
FR2765877B1 (fr) * 1997-07-10 1999-09-10 Oreal Composition comprenant une dispersion aqueuse de vesicules lipidiques a base de carbamates a chaine cholesteryle, utilisation notamment en cosmetique et nouveaux composes
AU3659497A (en) * 1997-07-11 1999-02-08 Canji, Inc. Organ-specific targeting of cationic amphiphile/retinobl astoma encoding dna complexes for gene therapy
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
EP1003711B1 (de) 1997-08-13 2001-11-07 Biontex Laboratories GmbH Neue lipopolyamine, deren darstellung und anwendung
CA2305768A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
EP1987845B1 (de) 1997-11-20 2012-03-21 Vical Incorporated Behandlung von Krebs mithilfe Cytokin-exprimierender Polynukleotide und Zusammensetzungen dafür
EP2036573A1 (de) 1998-06-17 2009-03-18 IDM Pharma, Inc. HLA-bindende Peptide und ihre Verwendungen
WO2000011019A1 (en) * 1998-08-21 2000-03-02 Felix Frey Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1059092B1 (de) * 1999-06-08 2005-12-07 Gentium S.p.A. Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
DE19944262A1 (de) * 1999-09-15 2001-03-29 Cardiogene Gentherapeutische S Pharmazeutische Zusammensetzung in Form eines Nukleinsäure-Lipid-Komplexes, ihre Herstellung und Verwendung in der Gentherapie
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AU2637500A (en) * 1999-12-10 2001-06-18 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
CA2415923C (en) 2000-07-12 2011-10-25 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1377165B1 (de) 2001-03-14 2009-07-01 Myriad Genetics, Inc. Tsg101-gag-wechselwirkung und ihre verwendung
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
EP1527341B1 (de) * 2001-11-20 2009-06-17 Duke University Grenzflächen-biomaterialien
EP1572933A4 (de) 2002-02-13 2007-09-05 Univ Duke Modulation der immunantwort durch polypeptide als antwort auf nichtpeptidischen bindungsstress
PT1515752E (pt) * 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
AU2004246905B2 (en) * 2003-06-18 2010-01-21 Biolab Ltd. Sphingoid polyalkylamine conjugates for vaccination
US7608699B2 (en) 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
US20060014289A1 (en) * 2004-04-20 2006-01-19 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060051396A1 (en) 2004-06-16 2006-03-09 Affinergy, Inc. Biofunctional coatings
SG156683A1 (en) 2005-06-07 2009-11-26 Univ Rockefeller STIMULATION OF PANCREATIC β CELL PROLIFERATION
WO2007005611A2 (en) 2005-06-30 2007-01-11 Whitehead Institute Progenitor cells and uses thereof
NZ569138A (en) * 2005-12-15 2012-06-29 Centre Nat Rech Scient Cationic oligonucleotides automated methods for preparing same and their uses
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
EP1844772A1 (de) * 2006-04-06 2007-10-17 Polyplus-Transfection SA Zubereitungen zur Transfektion von Oligonukleotiden zur Genabschaltung und deren biologischen und therapeutische Anwendungen
US20100159450A1 (en) 2006-06-23 2010-06-24 Susanne Wagner Dpyd gene variants and use thereof
PL2121713T3 (pl) 2007-01-18 2013-11-29 Genzyme Corp Oligosacharydy zawierające grupę aminooksylową oraz ich koniugaty
WO2009059011A2 (en) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
FR2925491B1 (fr) * 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
FR2926818B1 (fr) * 2008-01-30 2012-04-06 Centre Nat Rech Scient siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
EP2123256A1 (de) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorkohlenstoff-Nanoemulsionen mit Endozytose-verbessernder Oberfläche für die Genübertragung
WO2010042815A2 (en) * 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
CN102231952A (zh) * 2008-11-17 2011-11-02 安龙制药公司 用于核酸运载系统的可释放阳离子脂质
MX2011006347A (es) 2008-12-16 2011-09-06 Genzyme Corp Conjugados de oligosacaridos-proteinas.
EP2451475A2 (de) 2009-07-06 2012-05-16 Novartis AG Selbstreplizierende rna-moleküle und ihre verwendung
PT3178490T (pt) 2009-07-15 2022-06-30 Glaxosmithkline Biologicals Sa Composições de proteína f de rsv e métodos para produção das mesmas
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
ES2788863T3 (es) 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
US9011292B2 (en) 2010-11-01 2015-04-21 Nike, Inc. Wearable device assembly having athletic functionality
BR122022001262B1 (pt) 2010-11-15 2022-09-27 Life Technologies Corporation Compostos de transfecção contendo amina e complexo de transfecção
KR101904232B1 (ko) 2010-12-14 2018-10-05 내셔널 유니버시티 오브 싱가포르 뎅기 바이러스 세로타입 1 e 프로틴에 특이적인 인간 단일클론 항체 및 그들의 용도
TR201908715T4 (tr) 2011-01-26 2019-07-22 Glaxosmithkline Biologicals Sa Rsv immünizasyon rejimi.
RU2013151875A (ru) 2011-04-22 2015-05-27 Джензим Корпорейшн Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EP2729168A2 (de) 2011-07-06 2014-05-14 Novartis AG Immunogene zusammensetzungen und ihre verwendungen
EP2729165B1 (de) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
CA2872033A1 (en) 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
WO2013082500A2 (en) 2011-12-02 2013-06-06 Rhode Island Hospital Vaccine for falciparum malaria
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
WO2014097178A1 (en) * 2012-12-18 2014-06-26 Jawaharlal Nehru Centre For Advanced Scientific Research Antimicrobial compounds, their synthesis and applications thereof
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
DK2970955T3 (en) 2013-03-14 2019-02-11 Translate Bio Inc METHODS FOR CLEANING MESSENGER RNA
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
KR20230145545A (ko) 2013-04-07 2023-10-17 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
EP3060258A1 (de) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna-therapie für phenylketonurie
EP4276176A3 (de) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna-therapie für argininosuccinat-synthase-mangel
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
MX2016013965A (es) 2014-04-25 2017-01-09 Shire Human Genetic Therapies Metodos de purificacion de arn mensajero.
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
WO2016014839A2 (en) 2014-07-23 2016-01-28 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
EP3031822A1 (de) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus-Antigene
EP3757211A1 (de) 2014-12-19 2020-12-30 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
EP3047856A1 (de) 2015-01-23 2016-07-27 Novartis AG Cmv-antigene und ihre verwendungen
CN116196401A (zh) 2015-05-20 2023-06-02 博德研究所 共有的新抗原
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
US20230241207A1 (en) 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN106995384B (zh) * 2017-04-21 2018-12-11 郑州大学 具有抗菌活性的二烷基阳离子两亲性抗菌肽模拟物及其制备方法
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US11547666B2 (en) * 2018-05-30 2023-01-10 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
EP3841208A1 (de) 2018-08-24 2021-06-30 Translate Bio, Inc. Verfahren zur reinigung von messenger-rna
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
EP4004018A1 (de) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modifizierte humane cytomegalovirus-proteine
CN114746109A (zh) 2019-09-02 2022-07-12 居里研究所 靶向肿瘤新抗原性肽的免疫疗法
EP4048304A1 (de) 2019-10-22 2022-08-31 Institut Curie Auf tumor-neoantigene peptide abzielende immuntherapie
EP4149952A1 (de) 2020-05-12 2023-03-22 Institut Curie Neoantigene epitope in zusammenhang mit sf3b1-mutationen
CA3202176A1 (en) 2020-12-14 2022-06-23 Michael Steven ROONEY Tissue-specific antigens for cancer immunotherapy
CA3213002A1 (en) 2021-03-11 2022-09-15 Institut Curie Transmembrane neoantigenic peptides
KR20230172630A (ko) 2021-03-11 2023-12-22 므네모 테라퓨틱스 종양 네오 항원성 펩타이드
TW202332467A (zh) * 2021-10-29 2023-08-16 美商現代公司 脂質胺
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
US20230366001A1 (en) 2022-05-12 2023-11-16 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
WO1988000824A1 (en) * 1986-07-28 1988-02-11 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0490379A3 (de) * 1990-12-13 1992-06-24 BERLIN-CHEMIE Aktiengesellschaft Diaminosäurederivate und pharmazeutische Zusammensetzungen
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
ES2123133T3 (es) * 1993-03-10 1999-01-01 Magainin Pharma Derivados esteroidianos, composiciones farmaceuticas que contienen estos derivados esteroidianos y utilizacion de estos ultimos como antibioticos o desinfectantes.
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
DE59507224D1 (de) * 1994-12-28 1999-12-16 Max Delbrueck Centrum Neues cholesterolderivat für den liposomalen gentransfer

Also Published As

Publication number Publication date
AU716706B2 (en) 2000-03-02
WO1996018372A3 (en) 1996-09-06
JPH10510813A (ja) 1998-10-20
US6071890A (en) 2000-06-06
PT799059E (pt) 2002-11-29
AU4516196A (en) 1996-07-03
EP0799059A1 (de) 1997-10-08
ATE221390T1 (de) 2002-08-15
EP0799059B1 (de) 2002-07-31
DK0799059T3 (da) 2002-11-25
DE69527650D1 (de) 2002-09-05
WO1996018372A2 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
DE69527650T2 (de) Katonische amphiphile und plasmide für die intrazelluläre abgabe von therapeutischen mitteln
WO1998002190A3 (en) Cationic amphiphile/dna complexes
EP1019365B1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
CA2270396C (en) Cationic reagents for transfection
DE69729292T2 (de) Kurze externe führungssequenzen
US6858225B2 (en) Lipid-encapsulated polyanionic nucleic acid
Pichon et al. Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides
US20060147514A1 (en) Method for introducing antisense oligonucleotides into eucaryotic cells
CA3002744A1 (en) Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
DE69505677T2 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
DE69736385T2 (de) Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
Gruneich et al. Cationic corticosteroid for nonviral gene delivery
DK0852490T3 (da) Emulsionsformuleringer til tilførsel af nukleinsyrer til celler
JP2007505954A5 (de)
ES2180666T3 (es) Anfifilos cationicos y plasmidos para suministro intracelular de moleculas terapeuticas.
KR20130062953A (ko) 안티센스 올리고뉴클레오티드를 포함하는 약학 조성물 및 이의 사용 방법
DE60015957T2 (de) Selen enthaltendes vorstufearzneimittel für krebstherapie
Lavigne et al. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system
KR20090130056A (ko) 즉효형 핵산 송달용 캐리어 조성물
Walker et al. Chemistry and cellular aspects of cationic facial amphiphiles
DE10037861A1 (de) Mittel zur Therapie maligner Erkrankungen
Fimmel et al. Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells
US20210230596A1 (en) RIG-I Agonists and Methods of Using Same
EP2060262B1 (de) Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC
EP1724254A2 (de) Zubereitungen zur abgabe von negativ geladenen molekülen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation